This trial highlights the groundbreaking role of GLP-1 receptor agonists, traditionally used for managing diabetes, in reducing cardiovascular risk among individuals with overweight and obesity, even in the absence of diabetes. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.